Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed, PAR-24-306)
Support R01 projects that improve, validate, or credential mammalian cancer models (organoids, PDXs, GEMMs, companion animals, etc.) so they reliably predict human patient outcomes—drug response, metastasis, toxicity, early detection, immunotherapy, and related translational questions.
Eligibility Criteria
-
Organizations: U.S. or foreign Higher-Education Institutions; non-profit or for-profit organizations; local/state/federal governments; tribal or faith-based/community groups; public housing/Indian housing authorities; foreign entities (foreign components allowed).
-
Investigators: Any researcher(s) with the skills and resources to carry out translational cancer-model work. Multi-PI teams are permitted.
-
Nonresponsive Applications: Purely mechanistic/basic-research model development or projects lacking a clear translational aim.
Funding Details
-
Mechanism: R01 Research Project Grant (no clinical trials).
-
Direct Costs: Up to $499,000/year.
-
Project Period: Up to 5 years.
-
Anticipated Number of Awards: Dependent on available funds and merit.
-
Data Sharing: A Data Management & Sharing Plan is required.
Next Application Deadline
June 5 2025; October 5 2025; February 5 2026; June 5 2026 (all at 5:00 PM local time).
How to Apply
-
Access the FOA via ASSIST, Grants.gov Workspace, or your institution’s S2S system.
-
Follow R01 instructions; enter “PAR-24-306” in box 4B on the SF424(R&R) Cover.
-
No letter of intent required.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023